Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KYAT1 | Q16773 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393794 | 0.82 | GAA (0.58) | MAPTMEN1KMT2AGAAKYAT1 | |
| SCHEMBL4333571 | 0.80 | SMN1; SMN2 (0.45) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4333564 | 0.80 | SMN1; SMN2 (0.45) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL15682719 | 0.73 | MAPT (0.63) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL29052500 | 0.72 | KYAT1 (0.57) | MAPTMEN1KMT2AGAAKYAT1 | |
| SCHEMBL31728993 | 0.72 | KYAT1 (0.57) | MAPTMEN1KMT2AGAAKYAT1 | |
| SCHEMBL17572363 | 0.72 | ALDH1A1 (0.53) | MAPTMEN1KMT2AKYAT1SMN1; SMN2 | |
| SCHEMBL19086453 | 0.72 | ALDH1A1 (0.53) | MAPTMEN1KMT2AKYAT1SMN1; SMN2 | |
| SCHEMBL19086454 | 0.72 | ALDH1A1 (0.53) | MAPTMEN1KMT2AKYAT1SMN1; SMN2 | |
| SCHEMBL20022409 | 0.72 | KYAT1 (0.57) | MAPTMEN1KMT2AGAAKYAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653088-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-18 | — | — | US | disclosed |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | disclosed |
| US-7601718-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-13 | — | — | US | disclosed |
| US-20040192682-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | disclosed |
| WO-2004072029-A2 | PYRAZOLOPYRIDAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192682-A1 | Compositions useful as inhibitors of protein kinases | GSK3A, GSK3B, CSNK1A1 | MAPT 833/4885MEN1 1266/4885KMT2A 2215/4885 |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | GSK3A, GSK3B, GSKIP | MAPT 686/4885MEN1 1719/4885KMT2A 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.